Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Cedars-Sinai Medical Center

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
660
Shown on this page
12
Current sort
Recently updated
Campus scope
Cedars-Sinai Medical Center, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cedars-Sinai Medical Center, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 301–312 of 660 matching trials with a site at Cedars-Sinai Medical Center, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

Effect of Meal Timing During Adjuvant Treatment for Cancer

NCT07524218
Status at this site: Recruiting
Conditions
Cancer
Interventions
Time-restricted eating, Questionnaire Administration, Biospecimen Collection, Health coaching
Behavioral · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational

Project: Every Child for Younger Patients With Cancer

NCT02402244
Status at this site: Recruiting
Conditions
Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions
Cytology Specimen Collection Procedure, Medical Chart Review
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
75,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
246
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more
Active, not recruiting Phase 2 Interventional

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

NCT05554380
Site status not listed — check the official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
Active, not recruiting Phase 2 Interventional

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
Site status not listed — check the official record
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Recruiting Phase 2 Interventional

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296
Status at this site: Recruiting
Conditions
Endometrial Adenocarcinoma
Interventions
ACR-368, Gemcitabine, OncoSignature
Drug · Diagnostic Test
Lead sponsor
Acrivon Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
69
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
Status at this site: Recruiting
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

NCT03504956
Status at this site: Recruiting
Conditions
Coronary Atherosclerosis
Interventions
Cardiac MRI, Contrast, Beta blocker
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Phase 3 Interventional

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928
Status at this site: Recruiting
Conditions
Myocarditis Acute, Cancer
Interventions
Abatacept plus, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
29
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
Active, not recruiting Not applicable Interventional Results available

A Supervised Prehabilitation Program for Patients With Pancreatic Cancer

NCT05692323
Site status not listed — check the official record
Conditions
Pancreas Cancer
Interventions
PREHAB
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational

The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study

NCT03910569
Status at this site: Recruiting
Conditions
Takotsubo Cardiomyopathy
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Timeline
2019 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta, Aneurysm Thoracic, Aneurysm Dissecting, Transection Aorta, Intramural Hematoma
Interventions
Endovascular
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2038
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 19 more
Active, not recruiting Phase 3 Interventional Results available

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

NCT02521493
Site status not listed — check the official record
Conditions
Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions
Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
91 Days to 3 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
169
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more

About this Cedars-Sinai Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Cedars-Sinai Medical Center in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.